UBS Group’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $930K | Buy |
135,205
+63,285
| +88% | +$435K | ﹤0.01% | 4404 |
|
|
2025
Q1 | $207K | Sell |
71,920
-5,472
| -7% | -$15.8K | ﹤0.01% | 5298 |
|
|
2024
Q4 | $364K | Sell |
77,392
-3,241
| -4% | -$15.2K | ﹤0.01% | 4899 |
|
|
2024
Q3 | $288K | Sell |
80,633
-109,918
| -58% | -$392K | ﹤0.01% | 4438 |
|
|
2024
Q2 | $1.18M | Buy |
190,551
+117,783
| +162% | +$730K | ﹤0.01% | 3256 |
|
|
2024
Q1 | $687K | Buy |
72,768
+42,585
| +141% | +$402K | ﹤0.01% | 3849 |
|
|
2023
Q4 | $204K | Buy |
30,183
+19,026
| +171% | +$128K | ﹤0.01% | 4592 |
|
|
2023
Q3 | $49.5K | Sell |
11,157
-20,602
| -65% | -$91.5K | ﹤0.01% | 5165 |
|
|
2023
Q2 | $105K | Buy |
31,759
+31,335
| +7,390% | +$103K | ﹤0.01% | 4932 |
|
|
2023
Q1 | $1.21K | Sell |
424
-3,365
| -89% | -$9.59K | ﹤0.01% | 7680 |
|
|
2022
Q4 | $27.6K | Buy |
+3,789
| New | +$27.6K | ﹤0.01% | 6156 |
|
|
2022
Q2 | – | Sell |
-1,469
| Closed | -$35K | – | 9409 |
|
|
2022
Q1 | $35K | Buy |
1,469
+644
| +78% | +$15.3K | ﹤0.01% | 5815 |
|
|
2021
Q4 | $15K | Sell |
825
-480
| -37% | -$8.73K | ﹤0.01% | 7125 |
|
|
2021
Q3 | $37K | Buy |
1,305
+363
| +39% | +$10.3K | ﹤0.01% | 5451 |
|
|
2021
Q2 | $10K | Sell |
942
-579
| -38% | -$6.15K | ﹤0.01% | 6935 |
|
|
2021
Q1 | $18K | Buy |
1,521
+1,191
| +361% | +$14.1K | ﹤0.01% | 6439 |
|
|
2020
Q4 | $4K | Sell |
330
-2,896
| -90% | -$35.1K | ﹤0.01% | 6876 |
|
|
2020
Q3 | $26K | Sell |
3,226
-1,114
| -26% | -$8.98K | ﹤0.01% | 5237 |
|
|
2020
Q2 | $79K | Sell |
4,340
-3,773
| -47% | -$68.7K | ﹤0.01% | 4666 |
|
|
2020
Q1 | $97K | Buy |
8,113
+2,006
| +33% | +$24K | ﹤0.01% | 4460 |
|
|
2019
Q4 | $101K | Buy |
6,107
+1,664
| +37% | +$27.5K | ﹤0.01% | 4971 |
|
|
2019
Q3 | $29K | Buy |
+4,443
| New | +$29K | ﹤0.01% | 5547 |
|